Status:
COMPLETED
Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion
Lead Sponsor:
Ain Shams University
Conditions:
Complications
Eligibility:
All Genders
52-73 years
Phase:
EARLY_PHASE1
Brief Summary
A total of 80 patients will be randomly allocated into 2 groups, group A and placebo group using concealed envelope method.Group A patients (n= 40)will receive single dose intravenous infusions of iro...
Detailed Description
A total of 80 patients will randomly allocated into 2 groups, group A and placebo group using concealed envelope method.Group A patients (n= 40) will receive single dose intravenous infusions of iron ...
Eligibility Criteria
Inclusion
- patients aged 52-73 years old
- ASA II/III
- elective CABG
- hemoglobin level at baseline for males \>13.0 g/dl and for females \>12.0 g/dl.
Exclusion
- Patients with known hypersensitivity to iron sucrose
- history of hepatitis B or C or human immunodeficiency virus
- folate or vitamin B12deficiency, history of unstable angina,
- active severe infection
- suspicion of iron overload (ferritin \> 300 μg/l ), or autologous blood transfusion in the previous month pregnancy and nursing impaired renal function defined by s-creatinine \>150 μmol/L patients received any iron preparations in the previous month -
Key Trial Info
Start Date :
September 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04061655
Start Date
September 20 2019
End Date
January 10 2020
Last Update
January 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams university
Cairo, Egypt, 11566